In the phase III PENELOPE-B trial, it was found that palbociclib did not improve invasive disease-free survival when combined with endocrine therapy in HR-positive, HER2-negative breast cancer patients, especially those at high risk for recurrence following neoadjuvant chemotherapy.
In an update from the phase III PENELOPE-B trial, palbociclib did not improve invasive disease-free survival when added to endocrine therapy in patients with HR-positive, HER2-negative breast cancer who were considered to be at high risk for recurrence following neoadjuvant chemotherapy.
作者
匿名
推荐
暂无数据